Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.42 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
| ▸ | KLK1 | P06870 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15734691 | 1.00 | SRC (0.45) | SRCNAPEPLDPIK3CBPIK3CAPIK3CD | |
| SCHEMBL15733236 | 0.90 | TP53 (0.46) | NAPEPLDPIK3CBPIK3CAPIK3CDTACR1 | |
| SCHEMBL30796125 | 0.90 | TP53 (0.46) | NAPEPLDPIK3CBPIK3CAPIK3CDTACR1 | |
| SCHEMBL30795190 | 0.86 | SRC (0.45) | SRCNAPEPLDPIK3CBPIK3CAPIK3CD | |
| SCHEMBL2130723 | 0.86 | SRC (0.45) | SRCNAPEPLDPIK3CBPIK3CAPIK3CD | |
| SCHEMBL15733457 | 0.85 | SRC (0.46) | SRCSCD | |
| SCHEMBL30795503 | 0.85 | SRC (0.46) | SRCSCD | |
| SCHEMBL15733200 | 0.85 | KDM4E (0.48) | NAPEPLDPIK3CBPKMTSHRCRHBP | |
| SCHEMBL15328404 | 0.84 | SRC (0.49) | SRCKLKB1KLK1 | |
| SCHEMBL30794521 | 0.84 | SRC (0.44) | SRCNAPEPLDPIK3CBPIK3CAPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |